GLP-1受体激动剂治疗兴奋剂与尼古丁使用障碍的转化潜力
本文综述临床前及新兴临床证据,探讨胰高血糖素样肽-1受体(GLP-1R)激动剂重定位治疗精神兴奋剂使用障碍(PSUD)和尼古丁使用障碍(NUD)的潜力。临床前文献及新兴临床研究总体支持GLP-1R激动剂作为治疗PSUD和NUD等物质使用障碍的新型药物疗法的转化前景。
要点
- GLP-1R激动剂在动物模型中可减少精神兴奋剂和尼古丁介导的行为。
- 中枢内源性GLP-1神经环路参与自愿用药和觅药行为。
- 不断增长的临床前文献和新兴临床研究支持其转化潜力。
核心结论
- 不断增长的临床前文献和新兴临床研究支持GLP-1R激动剂作为治疗包括PSUD和NUD在内的物质使用障碍的新型药物疗法的转化潜力。
研究设计与样本
- 本综述总结了研究GLP-1R激动剂在PSUD和NUD动物模型中分别减少精神兴奋剂和尼古丁介导行为疗效的当前文献。
主要发现
- 近期临床前证据提示GLP-1R激动剂可重定位用于治疗PSUD和NUD。
- 综述还讨论了GLP-1R激动剂对药物介导行为抑制效应的神经机制,以及中枢内源性GLP-1神经环路在自愿用药和觅药行为中的作用。
临床怎么用
- PSUD和NUD影响全球数千万人,但PSUD尚无临床批准药物,现有NUD治疗长期疗效有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psychostimulant use disorder (PSUD) and nicotine use disorder (NUD) affect tens of millions of people worldwide, yet no clinically approved medications exist for PSUD, and existing NUD treatments have limited long-term efficacy. Recent preclinical evidence suggests that glucagon-like peptide-1 receptor (GLP-1R) agonists could be repurposed for treating PSUD and NUD. This review summarizes the current literature investigating the efficacy of GLP-1R agonists to reduce psychostimulant and nicotine-mediated behaviors in animal models of PSUD and NUD, respectively. The neural mechanisms underlying the suppressive effects of GLP-1R agonists on drug-mediated behaviors as well as the role of central endogenous GLP-1 neural circuits in voluntary drug-taking and drug-seeking behaviors are also discussed. Overall, a growing preclinical literature and emerging clinical studies support the translational potential of GLP-1R agonists as novel pharmacotherapies for treating substance use disorders including PSUD and NUD.
引用
- Herman RJ, Caffrey A, Pothikamjorn A, et al. Preclinical and Emerging Clinical Evidence Supporting the Translational Potential of GLP-1 Receptor Agonists for Treating Psychostimulant and Nicotine Use Disorders. Biol Psychiatry. 2026. PMID: 42142797. doi:10.1016/j.biopsych.2026.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。